Related Experiment Video
Updated: Jul 10, 2026
11:48
Genetic Manipulation of the Mouse Developing Hypothalamus through In utero Electroporation
Published on: July 24, 2013
DC ablation in mice: promises, pitfalls, and challenges.
Clare L Bennett1, Björn E Clausen
1Department of Haematology, University College London, Royal Free Hospital, London, UK. c.bennett@medsch.ucl.ac.uk
Trends in Immunology
|October 30, 2007
Summary
New transgenic mouse models allow researchers to deplete specific dendritic cell (DC) populations, advancing the study of immunity and tolerance. Understanding these models is crucial for interpreting results and refining future DC research.
Area of Science:
- Immunology
- Cell Biology
Background:
- Dendritic cells (DCs) are crucial for immune responses and tolerance.
- Understanding specific DC subset functions in vivo is vital for immunotherapy.
- Previous methods for depleting DC populations in mice have limitations.
Purpose of the Study:
- To discuss the impact of CD11c-DTR and Langerin-DTR mouse models on dendritic cell immunobiology.
- To highlight challenges in interpreting data from these inducible cell ablation models.
- To emphasize the need for refined transgenic strategies for DC subset depletion.
Main Methods:
- Utilizing inducible cell ablation through transgenic expression of a high-affinity diphtheria toxin receptor (DTR).
- Employing CD11c-DTR and Langerin-DTR mouse models for studying dendritic cell populations.
- Analyzing the effects of targeted DC depletion on immune responses.
Main Results:
- CD11c-DTR and Langerin-DTR models provide powerful tools for DC research.
- These models enable in vivo investigation of DC subset functions.
- Interpretation of data requires careful consideration of model-specific limitations.
Conclusions:
- Inducible DTR-based models represent a significant advancement in dendritic cell research.
- Further refinement of transgenic strategies is necessary to target additional DC subsets.
- Accurate interpretation of data from these models is key to advancing immunotherapy.
